Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
77.73
+0.72 (+0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
48
49
Next >
Gilead Appoints Cindy Perettie Executive Vice President of Kite
May 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
A Look Into Gilead Sciences' Debt
May 16, 2023
Via
Benzinga
GDC Stock Alert: Why Is GD Culture Group Up 106% Today?
May 16, 2023
GD Culture (GDC) stock is rocketing higher on Tuesday with investors reacting to the company's earnings report for Q1 2023.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
May 16, 2023
Via
Benzinga
Why Is Guardforce AI (GFAI) Stock Up Today?
May 16, 2023
Guardforce AI (GFAI) stock is on the rise Tuesday after the AI company announced the closing of a public share offering.
Via
InvestorPlace
Looking Into Gilead Sciences's Recent Short Interest
May 12, 2023
Via
Benzinga
Gilead Sciences Stock: Bear vs. Bull
May 12, 2023
The S&P 500 has outperformed Gilead over the past five years.
Via
The Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,300 Today
May 04, 2023
Via
Benzinga
GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?
May 16, 2023
Gilead Sciences (GILD) stock is a hot topic on Tuesday as a new price target predicts a roughly 28% upside for the shares.
Via
InvestorPlace
Gilead Sciences To Rally Around 28%? Here Are 10 Other Analyst Forecasts For Tuesday
May 16, 2023
Morgan Stanley raised the price target for DraftKings Inc. (NASDAQ: DKNG) from $23 to $25. Morgan Stanley analyst Stephen Grambling maintained an Overweight rating. DraftKings shares fell 0.2% to close...
Via
Benzinga
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
May 15, 2023
From
Arcus Biosciences
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
May 09, 2023
Via
Benzinga
Expert Ratings for Gilead Sciences
May 01, 2023
Via
Benzinga
Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript
April 28, 2023
GILD earnings call for the period ending March 31, 2023.
Via
The Motley Fool
Gilead Posts Bullish Cancer Drug Sales, But Profit Questions Linger
April 27, 2023
The company sells Trodelvy and two cell therapies. Sales of all three surged.
Via
Investor's Business Daily
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
May 09, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
American Express, Gilead Sciences And This US Oil Giant On CNBC's 'Final Trades'
May 08, 2023
On CNBC’s "Halftime Report Final Trades," Rob Sechan of New Edge Capital Group said Gilead Sciences, Inc. (NASDAQ: GILD) is a very defensive, steady growth play.
Via
Benzinga
2 Magnificent Dividend Stocks to Buy Before the Next Recession
May 05, 2023
The healthcare sector is a good place to find recession-proof stocks.
Via
The Motley Fool
TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference
May 04, 2023
Via
Investor Brand Network
Exposures
COVID-19
P/E Ratio Insights for Gilead Sciences
April 27, 2023
Via
Benzinga
What Does Gilead Sciences' Debt Look Like?
April 27, 2023
Via
Benzinga
Better Buy: Pfizer vs. Gilead
April 27, 2023
Pfizer and Gilead look cheap right now.
Via
The Motley Fool
Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years
May 04, 2023
Should you buy Gilead Sciences stock despite its poor track record?
Via
The Motley Fool
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
May 04, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
NanoViricides, Inc. (NYSE American: NNVC) Featured in Coverage of the Inaugural EF Hutton Global Conference
May 03, 2023
Via
Investor Brand Network
Exposures
COVID-19
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
May 02, 2023
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen
Via
Benzinga
Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits
May 02, 2023
Gilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help...
Via
Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
May 01, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
April 28, 2023
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.
Via
Investor's Business Daily
Gilead Sciences Announces First Quarter 2023 Financial Results
April 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.